OBJECTIVE: This prospective observational study explored the association of hypertensive disorders of pregnancy and small-for-gestational age with obstructive sleep apnea (OSA) as determined by screening measures for OSA and sleep studies. STUDY DESIGN: Two symptom-based screening questionnaires, the Berlin Questionnaire (BQ) and the Epworth Sleepiness Scale (ESS), were administered to enroll 1509 gravidae. Screen-positive subjects were referred for polysomnography. The primary outcome was the occurrence of either gestational hypertension or preeclampsia. Generalized linear models (GLM) were used to estimate the relative risks of associations. RESULT: One thousand one hundred and fifty-seven subjects were available for outcomes analysis. Screening positive on the BQ was positively associated with hypertensive disorders in GLM models (adjusted relative risk ¼ 1.90, 95% confidence interval 1.52 to 2.37). CONCLUSION: In this large prospective trial, GLM modeling suggests that the BQ but not the ESS demonstrated significant association with measured adverse pregnancy outcomes, and specific items predicted these outcomes better than others. However, causative association of BQ with OSA cannot be assumed.
INTRODUCTION
The obesity epidemic persists, and maternal obesity is an ongoing contributor. Data from 2004 to 2005 revealed the prevalence of maternal obesity to be 20% overall, and this prevalence is projected to increase. 1, 2 Maternal obesity increases the risk of several adverse maternal and perinatal outcomes. 3, 4 Obesity is also a risk factor for obstructive sleep apnea (OSA), a condition of increased interest due to its seemingly intertwined relationship with not only obesity but also possibly hypertensive disorders and fetal growth restriction. [5] [6] [7] OSA is characterized by recurrent cessation of respiratory airflow resulting from upper airway inspiratory collapse during sleep. 8 It has been suggested that pregnant women may be predisposed to OSA, and OSA may contribute to adverse pregnancy outcomes. [5] [6] [7] [8] [9] [10] However, obesity has been posited to be a primary confounder in interpreting the available evidence on the risk of OSA to adverse pregnancy outcomes. 10, 11 Using a wellcharacterized prospective cohort of at-risk gravidae, we previously demonstrated that the relationship between OSA and obesity is likely inextricably linked in pregnancy, but that OSA potentially exerts an independent influence on outcomes. 10 Limitations to our previous analysis included gravidae being recruited from a high-risk clinical population, as well as lack of confirmative diagnostic testing with polysomnography (PSG) among subjects. 10 In this current study, we sought to delineate the effect of OSA diagnosis and OSA symptoms (that is, positive screening measures) on pregnancy outcomes in a population-based cohort of gravidae. We hypothesized that a diagnosis of OSA would be associated with gestational hypertension (GHTN), preeclampsia, and small-for-gestational age (SGA) after stratifying by obesity status. To accomplish these objectives, recruited subjects were screened for OSA as detailed below referred for PSG, and perinatal outcomes were collected and compared.
METHODS
This study was performed in the Harris County Hospital District (now Harris Health System) between May 2010 and September 2012. The study was approved by the Institutional Review Board at the Baylor College of Medicine and Harris County Hospital District, and written informed consent was obtained. Gravidae presenting to two community clinics and one tertiary clinic were approached for enrollment. Consenting subjects were administered a questionnaire (in English or Spanish), which comprised the Epworth Sleepiness Scale (ESS), the Berlin Questionnaire (BQ) and questions collecting basic demographic and health information. Women of all gestational ages were recruited. Inclusion criteria were gravidae aged 18 to 50 years. Exclusion criteria were subjects with known sleep-disordered breathing, multi-fetal gestation, fatal fetal anomalies, and subjects with significant underlying pulmonary or cardiac comorbidities. As this study examined perinatal outcomes, enrolled subjects who ultimately terminated their pregnancy, miscarried, or delivered at a non-study site were not included for outcomes' analysis.
The self-administered questionnaire contained ESS and BQ. The ESS and BQ were chosen due to their frequent use in the obstetric OSA literature and possibly the population. [12] [13] [14] [15] [16] The ESS has been validated in the Spanish language and in Hispanic populations. [17] [18] [19] At study initiation, neither questionnaire had been validated in a gravid population; a separate analysis of this study sought to assess the validity of these two questionnaires in pregnancy. We suspected that the BQ may perform poorly based upon the findings of our previous prospective trial on OSA in pregnancy and fetal heart rate monitoring wherein we found a sensitivity and specificity of 35.0% and 63.8% for BQ; however, this study was not designed specifically to assess the predictive value of the BQ. 16 While this current study was ongoing, the validity of ESS and BQ in pregnancy were demonstrated to be poor. 13 Data from 2012 show that ESS has a sensitivity of 36% and specificity of 77% in pregnancy: BQ has a sensitivity of 39% and specificity of 68%. 13 The BQ questions were developed to elicit factors or behaviors that consistently predicted the presence of sleep-disordered breathing. 20 In nonpregnant adults, it has a sensitivity of 86% and specificity of 77%. 20 The  10 questions are divided into three categories: snoring is queried with a  header question and 4 follow-up questions, daytime sleepiness is queried  with 3 questions and a follow-up question about sleeping while driving a  motor vehicle, and medical risk factors are queried by asking about the  presence of high blood pressure and obesity (by asking the height and  weight) . 20 A high-risk or 'screen-positive' individual is reported to have at least two out of the three symptom categories positive in the questionnaire. 20 Responses to the height, weight and high blood Figure 1 . Study design. On enrollment, subjects would complete the Epworth and Berlin Questionnaire. To capture all possible cases of obstructive sleep apnea (OSA), enrollees with evidence of OSA based upon either criterion would be classified as screening positive for OSA and referred for polysomnography (PSG). After delivery, outcomes would be compared. CPAP, continuous positive airway pressure. Figure 2 . Enrollment and study flow. One thousand and five hundred and nine subjects were eligible for enrollment. Of those, 1048 screened negative on at least one of the measures and 5 did not adequately complete either screening measure. For the purposes of study design, they were treated as obstructive sleep apnea (OSA) screen negative as they did not test positive on either measure. Of the 456 subjects who screened positive on at least one measure, only 58 completed diagnostic testing via polysomnography (PSG) or type 3 unattended home sleep testing device (T3D). Additionally, subjects who had a termination of pregnancy or miscarried and subjects who delivered at a nonstudy site (NSS) did not have outcomes available for analysis, thus were excluded from outcomes analysis. The number and percentage of subjects with outcomes available are shown. pressure (chronic hypertension) items on this questionnaire were confirmed by review of the medical record.
Regarding the ESS, in nonpregnant subjects, ESS has a sensitivity of 66% to 93.5% and specificity from 48% to 100%. 21, 22 The ESS consists of eight questions that evaluate the tendency to 'doze off' in certain situations and is a subjective measure of sleepiness. 21, 23 The situations in the questions themselves range from highly soporific, such as 'Lying down to rest in the afternoon when circumstances permit' to non-soporific, such as 'In the car, while stopped for a few minutes in traffic'. 23 The responses are on a scale of 0 to 3 signifying: 0 ¼ no chance of dozing off, 1 to 2 ¼ light to moderate chance of dozing off, and 3 ¼ high chance of dozing off. For this study, we considered a patient to screen positive for OSA with an ESS of X10.
Screen-positive subjects were referred for attended PSG at the Harris County Hospital District Sleep Disorders Center. Due to resource constraints, diagnostic testing was only performed on subjects suspected of having OSA. As there are aspects of validity to each screening measure, all enrollees with evidence of this condition based on either ESS or BQ were classified as screening positive for OSA and were referred for an attended PSG ( Figure 1 ). 16 Subjects were notified of their screen-positive status via telephone call and letter. Referrals were performed via an order in the electronic medical record. Orders were also faxed and the Sleep Center was called to schedule studies. Due to limitations in completing PSGs, the protocol was amended to allow the use of a modified sleepscreening study to be performed inpatient if a screen-positive patient was admitted to the antepartum service for any indication.
Attended PSG testing was performed using a Carefusion Somnostar polysomnography system (CareFusion, Yorba Linda, CA, USA). Via this multi-channel system, the following variables were monitored continuously: electroencephalography, electrocardiography, electro-oculography, submental and leg electromyography, electrocardiography, heart rate monitoring, pulse-oximetry, nasal airflow, body position and movements, and snoring. Attended PSG tests were administered by a certified technologist, and studies were reviewed by a physician, board certified in sleep medicine. OSA was diagnosed with Respiratory Disturbance Index45 using attended PSG. Attended PSG was scored using the American Academy of Sleep Medicine Manual for the Scoring of Sleep and Associated Events, 2007. 24 The ResMed ApneaLink Plus (ResMed, MAP Medizin Technologie GmbH, Poway, CA, USA) is a type 3 unattended home sleep testing device (T3D) which generates a report with the AHI (apnea hypopnea index), among other variables. Compared with PSG, it has a sensitivity and specificity of 67.5% and 76.9% (for 'home' or unmonitored use), using an AHIX5 considered diagnostic of OSA, 25 as it was in this study. This device has not been validated in pregnancy but has been used in previous obstetric studies as diagnostic. 10, 16, 26 For the purposes of this study, T3D was performed in the hospital, not at home, and was considered diagnostic. However, if a T3D was performed, the referral for PSG was not cancelled as PSG remains the standard for diagnosis.
Following delivery, each subject's medical chart was reviewed and outcomes were extracted (KM Antony). Our primary outcome was the incidence of GHTN or preeclampsia. Secondary outcomes included Perinatal outcomes in OSA screen-positive gravidae KM Antony et al gestational diabetes and unscheduled cesarean delivery. The diagnosis of GHTN, preeclampsia and severe preeclampsia were consistent with the definitions by the American Congress of Obstetricians and Gynecologists at the time of the study (2010 to 2012). 27 GHTN was defined as a systolic blood pressure of X140 mm Hg or a diastolic blood pressure of X90 mm Hg that occurs after 20 weeks of gestation in a woman with previously normal blood pressure without proteinuria. The criteria for preeclampsia was identical to the criteria for GHTN with the exception that proteinuria of 0.3 g in a 24 h period was required. Severe preeclampsia was diagnosed if any of the following were present: blood pressure of X160 mm Hg or a diastolic blood pressure of X110 mm Hg on two occasions at least 6 h apart while on bed rest, proteinuria of 5 g in a 24 h period or X3 þ on two random urine samples collected at least 4 h apart, oliguria of o500 ml in 24 h, cerebral or visual disturbances, pulmonary edema or cyanosis, epigastric or right upper quadrant pain, impaired liver function, thrombocytopenia, or fetal growth restriction. 27 Similarly, the diagnosis of gestational diabetes was congruous with the definition by the American Congress of Obstetrics and Gynecology. 28 Unplanned cesarean deliveries included deliveries for labor dystocias, fetal heart rate tracing abnormalities and suspected macrosomia. Unscheduled cesarean deliveries that were performed at a non-scheduled time, such as cases performed owing to previous uterine surgery, malpresentation, placental location, fetal anomalies (precluding vaginal delivery) or infectious reasons, were not counted as unplanned cases. The neonatal outcome of greatest interest was the occurrence of SGA due to its previous association with snoring 29 and sleep-disordered breathing. 30 Other neonatal outcomes were birth weight ratio, preterm delivery, nursery level required and large-for-gestational age. SGA was defined as o10th percentile. 31 A second category ofo5th percentile was also examined. Largefor-gestational age was defined as490th percentile, and a second category of495th percentile was also examined. The occurrence of preterm birth, SGA, large-for-gestational age or level 2 or 3 nursery admission comprised the composite neonatal outcome. As a second means of representing birth weight, birth weight ratio was calculated in each case as birth weight divided by mean birth weight for gestational age and is a previously validated measure of adjusting for gestational age in a study population. 32 Covariates considered in these analyses were maternal age, race/ ethnicity, smoking, parity, gestational age, prepregnancy body mass index (BMI), hypertension and pregestational and gestational diabetes. Prepregnancy BMI categories were defined according to the National Institute of Health and the World Health Organization: normal weight 19 to 24.9 kg m À 2 , overweight 25 to 29.9 kg m À 2 , and obese 430 kg m À 2 . 33, 34 BMI was calculated using height and weight data (kg m À 2 ) that were collected during initial assessment. When prepregnancy weight was not known, the earliest available weight was used.
Our sample size estimation was based upon having adequate power to examine the relationship between OSA and maternal and neonatal outcomes described above, adjusted for the possible confounding influence of obesity. In our previous analysis of n ¼ 100 subjects, we found the screen-positive rate for OSA to be 36% (by BQ alone) and overall OSA diagnosis-positive rate of 20%. In this analysis, we found the incidence of preeclampsia to be 1.95-fold higher among women screening positive for OSA than among women screening negative (14.3% versus 7.3%). 10 In order to detect a similar increase in preeclampsia or GHTN, we estimated that we would need a minimum of 243 OSA positive subjects. In order to arrive at this sample size, a minimum of 1100 subjects would need to be screened with PSG performed in 45% of subjects, which was our estimated screen-positive rate after adding ESS to the estimated screen-positive rate of 36% for BQ. 10 This would ultimately give us three cohorts in which to follow outcomes: screen negative, screen positive/ PSG negative (that is: false positive) and OSA positive. After 500 subjects were enrolled, the protocol was amended; enrollment was increased to 1600 (increased by 500) as only four diagnostic PSGs had been completed (of the 150 referred for PSG).
Descriptive findings of study sample characteristics and outcomes by OSA screening results from the BQ, ESS and OSA diagnosis based on T3D or PSG are reported. Chi-squared testing, student t test, or Fisher's exact test were performed.
Generalized linear models' adjusted relative risks (aRRs) with 95% confidence intervals (CIs) were estimated to examine the relationships between screening OSA positive on the BQ, ESS, their individual items and adverse maternal and neonatal outcomes. BMI and hypertension were added in models examining other BQ items and adverse maternal and neonatal outcomes to control for confounding. Stratified by BMI, additional generalized linear models and crude RRs (cRR) and adjusted RRs (aRR) with 95% CIs were obtained among normal weight, overweight and obese groups for associations between the BQ, BQ items and adverse maternal and neonatal outcomes.
Fisher's exact test was used to examine differences in sample characteristics by OSA diagnosis from three-channel sleep screening or PSG. Statistical significance for all analyses was Po0.05. Stata 10.0 (Stata, College Station, TX, USA) and SPSS 13.0 (SPSS, Chicago, IL, USA) were used for analyses.
RESULTS
One thousand six hundred and seventeen questionnaires were completed, and clinical information was analyzed for previously unidentified exclusion criteria ( Figure 2 ). Subjects who Perinatal outcomes in OSA screen-positive gravidae KM Antony et al subsequently terminated their pregnancy (n ¼ 1), miscarried (n ¼ 32) or who delivered at a non-study site (n ¼ 319) had no perinatal outcomes available for analysis and were similarly excluded from outcomes' analysis. As shown in Figure 2 , 1157 subjects had perinatal outcomes available. The number of subjects who completed either the BQ or ESS were 1153. As shown in Table 1 , the majority of women were Hispanic (91.2%) and non-smokers (97.3%). Over three-fourths of the subjects were overweight (35.4%) or obese (42.1%). At baseline, screening positive for OSA was associated with non-Hispanic race/ ethnicity, smoking, obesity and hypertension. Specifically, only 27.2% of Hispanic gravidae screened positive for OSA compared with 59.9% of African/African Americans, 51.4% of Caucasians and 37.6% of other races. The majority of patients were screened in the second or third trimester; screening positive was not associated with the trimester of screening. Overall, the screen-positive rate varied from 30.2% in the first trimester to 27.5% in the second trimester and 31.5% in the third trimester.
Overall, 15.5% (n ¼ 178 of 1152) of subjects screened positive on BQ and 19.0% (n-205 of 1081) screened positive on ESS. Overall, among women with outcomes available, 33.1% (n ¼ 383 of 1157) women screened positive on either the BQ or ESS. The aRR of screening positive on BQ by BMI was 1.28 (95% CI 0.58 to 2.82, non-significant) and 9.03 (95% CI 4.68 to 17.39, significant) compared with normal weight gravidae for overweight and obese gravidae, respectively. Of women with outcomes available undergoing sleep testing, 18.2% (n ¼ 8 of 44) were diagnosed with OSA. Table 2 illustrates the percentage distribution of adverse maternal and neonatal outcomes by OSA screening results. Unadjusted analyses indicate screening OSA positive on the BQ was associated with preeclampsia (Po0.001) and GHTN or preeclampsia (pooled) (Po0.001). Screening positive on BQ was not associated with SGA; associations with other neonatal outcomes are shown. The ESS was not significantly associated with any examined outcomes. Average BW ratios were compared between the OSA screen-negative and OSA screen-positive groups. The average BW ratios were 0.96 (s.d. 0.13) and 0.97 (s.d. 0.15), respectively, with no statistically significant difference between the groups (P ¼ 0.19). Table 3 shows the RRs of adverse maternal and neonatal outcomes and screening OSA positive on the BQ and its items adjusting for confounding. In the adjusted models for the BQ, it was associated with preeclampsia or GHTN (pooled) (aRR ¼ 1.90, 95% CI 1.52 to 2.37) and preeclampsia (aRR ¼ 2.45, 95% CI 1.84 to 3.26). Specific BQ items were also associated with perinatal outcomes as delineated in Table 3 . Of note, BMI430 kg m À 2 was similarly associated with GHTN and preeclampsia (aRR ¼ 1.70 and 1.55 with 95% CI 1.18 to 2.46 and 1.16 to 2.07, respectively), yet a negative association was observed for BMI430 kg m À 2 and SGAo10th percentile (aRR ¼ 0.69, 95% CI 0.50 to 0.96). The BQ items regarding snoring that bothers others, feeling tired after sleeping and feeling tired during waking time were not associated with any primary outcomes (data not shown). Feeling tired during waking time was inversely associated with gestational diabetes (aRR 0.67, 95% CI 0.49 to 0.92) (data not shown).
Stratified by BMI, the association between screening positive for OSA and hypertensive disorders remained. These results are summarized in Table 4 and described in further detail in Supplementary Tables S1-S3. Even among normal weight subjects (Table 4 and Supplementary Table S1 , n ¼ 261), screening positive for OSA was associated with preeclampsia or GHTN (pooled) with a cRR of 2.80 (95% CI 1.05 to 7.50) and an aRR of 2.70 (95% CI 1.06 to 6.83) after controlling for confounding variables. Among overweight subjects (Table 4 and Supplementary Table S2 , n ¼ 409), screening positive on the BQ was associated with preeclampsia or GHTN (pooled) (cRR 2.95, 95% CI 1.86 to 4.69, aRR 2.80, 95% CI 1.79 to 4.37) and also preeclampsia (cRR 4.41, 95% CI 2.57 to 7.57, aRR 3.87, 95% CI 2.41 to 6.24) and severe Perinatal outcomes in OSA screen-positive gravidae KM Antony et al preeclampsia (cRR 6.16, 95% CI 3.28 to 11.55, aRR 4.97, 95% CI 2.89 to 8.54). Additionally, among obese subjects (Table 4 and Supplementary Table S3 , n ¼ 487), screening positive on the BQ was associated with preeclampsia or GHTN (pooled) with a cRR 1.46 (95% CI 1.10 to 1.92, aRR 1.35 (95% CI 1.03 to 1.77) and preeclampsia (cRR 1.90, 95% CI 1.33 to 2.73, aRR 1.78, 95% CI 1.23 to 2.56). The RRs of neither the primary outcome (preeclampsia or GHTN) nor SGA were significantly associated with screening positive on the ESS after adjusting for confounding variables. ( Supplementary  Table S4 ) Analysis of screen negative versus false-positive and truepositive gravidae was not performed due to the limited number of PSG/T3D (12.8% of the screen-positive subjects), which were ultimately performed. Table 5 shows the percentage distribution of women diagnosed with OSA (based upon positive PSG or T3D) among tested screen-positive subjects by study characteristics and OSA screening measures. The proportion of gravidae diagnosed with OSA (with outcomes available) was 18.2% (n ¼ 8) among those tested. There was a significant difference in the gestational age at the time of survey; more subjects who screened positive in the second trimester were diagnosed with OSA. As shown in Supplementary Table S5 , positive OSA diagnosis was not associated with adverse maternal and neonatal outcomes compared with subjects who screened positive for OSA but tested negative.
DISCUSSION
Obesity is a risk factor for adverse perinatal outcomes. Obesity and OSA are inextricably linked in nonpregnant adults, and there is physiological evidence that pregnancy may predispose to OSA, thus compounding the pre-existing risk in obese gravidae. 8, 10, 11, 35 In this study, we sought to delineate the effect of OSA from obesity on perinatal outcomes and found that OSA was independently associated with adverse outcomes. We also sought to delineate the effect of OSA symptoms from OSA diagnosis by comparing the outcomes of false-positive subjects with subjects diagnosed with OSA; this analysis was not able to be fully realized due to low PSG completion.
Using both adjusted and unadjusted analyses, we found that screening positive for OSA on BQ was associated with hypertensive disorders across all BMI strata. Even among overweight and obese gravidae, the cRR was 4.41 and 1.90 (aRR 3.87 and 1.78), respectively, thus screening positive for OSA compounds the already elevated risk of preeclampsia among these gravidae. Also notable is the risk of preeclampsia with screening positive on BQ among subjects with a normal prepregnancy weight, demonstrating that the risk of preeclampsia is increased with screening positive on BQ, even among normal weight gravidae. Individual items were also commonly associated with hypertensive disorders and neonatal outcomes, namely snoring and dozing off while driving. The association of hypertension with preeclampsia was expected.
ESS was not associated with any outcomes. This could be partly explained by the frequency of sleepiness in pregnancy, which may make this a poor screening symptom for OSA and thereby less likely to be associated with outcomes. BQ was expected to have associations with outcomes based on the snoring questions, given their previous association with hypertensive disorders. 11, 29, 36 However, it was also expected to have associations with outcomes due to the inherent confounding by co-morbid conditions, namely BMI and HTN, which are components of the BQ.
These findings are consistent with many, but not all, previous studies that note an association between OSA diagnosis or screening OSA positive and preeclampsia. 10, 11, 30, 37, 38 Many, however, concluded that obesity was either the primary contributor to the risk of preeclampsia or a significant confounder. 8, 10, 11, 35 Unlike many previous studies, this study rigorously adjusted for confounding variables, including BMI.
When compared with false-positive subjects, we found no association between OSA diagnosis by T3D/PSG and perinatal outcomes. However, only 45 of the 58 subjects who underwent testing had available outcomes. Additionally, given the overall low number of PSGs that were completed, the analysis of outcomes among subjects with testing was ultimately underpowered. Although there was no association of the gestational age at survey and screening positive on the survey (Table 1) , among those who screened positive and completed diagnostic testing, there was a significant difference in the gestational age at the time of survey and having a confirmed diagnosis of OSA (Table 5 ). Notably, the gestational age at the time of diagnostic testing was not associated with being diagnosed with OSA (Table 5 ). Together, this suggests that, if screening occurs, it may be most useful in the second trimester.
Strengths of this paper include its large sample size, prospective design, adjustment for confounding and item-by-item analysis that adjusted for confounding as well. This study also faced the same resource limitations faced by practitioners in obtaining diagnostic testing, which may enhance its applicability to clinical practice. As screening seems to predict adverse outcomes and previous studies have demonstrated that treatment may decrease these outcomes, 39 perhaps payers would ultimately benefit from coverage of attended PSG in pregnancy.
The main limitation of this study was the small number of subjects who completed attended PSG testing. Briefly, all the 456 screen-positive subjects were referred for PSG; due to sleep center availability, lack of insurance coverage and subjects' social obligations and needs, only eight were completed. This prompted the use of the T3D as diagnostic of OSA, which has not been validated in pregnancy. Briefly, this T3D has a lower sensitivity at low levels of AHI, which are common in (non-pregnant) women, thus its use as a diagnostic tool in pregnancy may be limited. 25, 40, 41 In this setting, the low sensitivity of T3D compared with PSG may have resulted in falsely negative 'diagnostic' tests, compared with PSG. This may contribute to the lack of association between OSA 'diagnosis' in this study and the primary outcome.
The Hispanic majority of this study is both a strength and a weakness. It adds to the overall limited existing literature on OSA in the Hispanic population. The impact of ethnicity on pregnancy outcomes in OSA is largely unknown; this study found that, even after controlling for ethnicity, screening positive for OSA was associated with outcomes. However, the Hispanic majority may limit the applicability of this study to populations with different demographics. Future research on OSA in pregnancy in the Hispanic population may be warranted.
Consistent with previous studies, the present investigation shows that obesity is a risk factor for screening positive for OSA, which was expected as obesity is a weighted component of the BQ. More importantly, the association between screening positive for OSA and adverse outcomes remains after controlling for obesity. As a point of caution, screening positive for OSA on BQ is not synonymous with a diagnosis of OSA; indeed, we and others have found that BQ poorly predicts OSA diagnosis among gravidae. 10, 13, 16 However, even in the absence of an actual OSA diagnosis, our results suggest that the risk of adverse outcomes arises from the combination of habitus and symptoms, indicating a far more complex relationship that will require further study and the use of OSA screening measures adapted to pregnant women.
